4basebio (4BB)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 1,110.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 1,820.00
  • 52 Week Low: 1,095.46
  • Currency: UK Pounds
  • Shares Issued: 15.50m
  • Volume: 0
  • Market Cap: £172.01m

Growth Ratings

EPS Growth shows the relative growth of a company's earnings over the last year.

The rise in total monies receivable for goods / services sold before expenses.

1yr EPS Growth Not Available
1yr Revenue Growth
86.49% above the market average86.49% above the market average86.49% above the market average86.49% above the market average86.49% above the market average
65.52% above the sector average65.52% above the sector average65.52% above the sector average65.52% above the sector average65.52% above the sector average

Income Ratings

The percentage of the share price that a company pays out as dividends over a year.

The percentage change from the previous year in the dividend paid on each share.

Dividend Yield Not Available
1yr DPS Growth Not Available

Valuation Ratings

The share price as a ratio of revenue per share.

The share price as a ratio of net asset value.

Price Sales Ratio
94.05% above the market average94.05% above the market average94.05% above the market average94.05% above the market average94.05% above the market average
92.00% above the sector average92.00% above the sector average92.00% above the sector average92.00% above the sector average92.00% above the sector average
Price Book Ratio
85.83% below the market average85.83% below the market average85.83% below the market average85.83% below the market average85.83% below the market average
47.37% below the sector average47.37% below the sector average47.37% below the sector average47.37% below the sector average47.37% below the sector average

Performance Ratings

In percentage total change in share price over 30 days.

In percentage total change in share price over 3 months.

Price Chg 30d
55.38% below the market average55.38% below the market average55.38% below the market average55.38% below the market average55.38% below the market average
39.13% below the sector average39.13% below the sector average39.13% below the sector average39.13% below the sector average39.13% below the sector average
Price Chg 3m
27.72% below the market average27.72% below the market average27.72% below the market average27.72% below the market average27.72% below the market average
8.70% above the sector average8.70% above the sector average8.70% above the sector average8.70% above the sector average8.70% above the sector average

Technical Ratings

The Relative Strength Index measures a share price relative to itself and its recent history.

Momentum is an oscillator that measures the rate of price change.

RSI
83.89% below the market average83.89% below the market average83.89% below the market average83.89% below the market average83.89% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Momentum 20
89.26% below the market average89.26% below the market average89.26% below the market average89.26% below the market average89.26% below the market average
90.48% below the sector average90.48% below the sector average90.48% below the sector average90.48% below the sector average90.48% below the sector average

Management Ratings

Operating Margin is profit as a percentage of sales.

Return on capital employed measures the return from invested and borrowed capital.

Operating Margin
93.15% below the market average93.15% below the market average93.15% below the market average93.15% below the market average93.15% below the market average
80.65% below the sector average80.65% below the sector average80.65% below the sector average80.65% below the sector average80.65% below the sector average
ROCE Not Available

Profitability Ratings

Earnings per share, the company's profitability expressed on a per share basis.

Analysts' estimates of future EPS for the next 2 years.

EPS
52.48% below the market average52.48% below the market average52.48% below the market average52.48% below the market average52.48% below the market average
2.22% below the sector average2.22% below the sector average2.22% below the sector average2.22% below the sector average2.22% below the sector average
Forecast EPS Not Available

Profit/Loss Ratings

Monies produced from sales of goods and services after trade discounts, VAT, etc.

Operating Profit is the profit after deducting operating costs from gross profits.

Turnover
81.29% below the market average81.29% below the market average81.29% below the market average81.29% below the market average81.29% below the market average
54.84% below the sector average54.84% below the sector average54.84% below the sector average54.84% below the sector average54.84% below the sector average
Operating Profit Loss
85.01% below the market average85.01% below the market average85.01% below the market average85.01% below the market average85.01% below the market average
51.11% below the sector average51.11% below the sector average51.11% below the sector average51.11% below the sector average51.11% below the sector average

Balance Sheet Ratings

The difference between current assets and current liabilities.

A current asset representing the company's financial liquidity.

Assets
8.78% above the market average8.78% above the market average8.78% above the market average8.78% above the market average8.78% above the market average
31.82% above the sector average31.82% above the sector average31.82% above the sector average31.82% above the sector average31.82% above the sector average
Cash
45.48% above the market average45.48% above the market average45.48% above the market average45.48% above the market average45.48% above the market average
54.55% above the sector average54.55% above the sector average54.55% above the sector average54.55% above the sector average54.55% above the sector average

Director Deal Ratings

The cumulative amount of stocks sold by company directors over 1 year

The cumulative amount of stocks bought by company directors over 1 year

Sells 1y
17.11% above the market average17.11% above the market average17.11% above the market average17.11% above the market average17.11% above the market average
16.67% above the sector average16.67% above the sector average16.67% above the sector average16.67% above the sector average16.67% above the sector average
Buys 1y
70.80% above the market average70.80% above the market average70.80% above the market average70.80% above the market average70.80% above the market average
51.72% above the sector average51.72% above the sector average51.72% above the sector average51.72% above the sector average51.72% above the sector average

Broker Ratings

The percentage of stockbrokers that rate the company as a Buy

The percentage of stockbrokers that rate the company as a Hold

Brokers Percent Buy Not Available
Brokers Percent Neutral Not Available

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

4basebio Market Data

Currency UK Pounds
Share Price 1,110.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 1,820.00
52 Week Low 1,095.46
Volume 0
Shares Issued 15.50m
Market Cap £172.01m

4basebio Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
67.42% below the market average67.42% below the market average67.42% below the market average67.42% below the market average67.42% below the market average
13.04% below the sector average13.04% below the sector average13.04% below the sector average13.04% below the sector average13.04% below the sector average
Price Trend
15.29% below the market average15.29% below the market average15.29% below the market average15.29% below the market average15.29% below the market average
26.09% above the sector average26.09% above the sector average26.09% above the sector average26.09% above the sector average26.09% above the sector average
Income Not Available
Growth
57.33% above the market average57.33% above the market average57.33% above the market average57.33% above the market average57.33% above the market average
73.33% above the sector average73.33% above the sector average73.33% above the sector average73.33% above the sector average73.33% above the sector average

4basebio Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

4basebio Key Personnel

CEO Heikki Lanckriet
CFO David John Roth

Top of Page